King of Prussia’s CSL Behring has received more positive news for its autoimmune and inflammatory disease disorder drug Privigen, as the FDA has approved it for a third use, writes John George for Philadelphia Business Journal.

Earlier this summer, the drug was approved for treating primary immunodeficiency, the generic condition that makes the immune system shut down when attempting to fight off infection.

Privigen has also been approved to treat chronic immune thromboctopenic purpura which causes excessive bruising and bleeding.

This latest approval from the FDA, allows Privigen to be used as a treatment for chronic inflammatory demyelinating polyneuropathy.

CIDP is a rare autoimmune disorder that affects a person’s peripheral nerves and can cause permanent nerve damage.

[uam_ad id=”54865″]

According to Dr. Andrew Cuthbertson, chief scientific officer and director of research and development for CSL Ltd., CSL Behring’s parent company, the new FDA approval supports the focus of the company on building a leading neurology franchise.

“We continue to advance clinical research to determine innovative and improved uses of immunoglobulin therapy that can benefit patients and improve their quality of life,” said Dr. Cuthbertson.

Read more about the new use for CSL Bering’s drug at Philadelphia Business Journal by clicking here.

[uam_ad id=”54875″]